NVCR Novocure

NASDAQ
$16.95

Novocure (NVCR) is expected to report earnings on October 22, 2026, before the market open. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -5.8% since its last earnings release on July 23, 2026.

Novocure Beat Consensus Estimates, Raises Guidance, but Remains In-line with Estimates
Thursday, July 23, 2026 · 7:00 AM ET
Earnings Date
3rd Quarter, Sep 2026
Oct 22
Thursday · 7:00 AM ET
Earnings Whisper
-
vs ($0.21)
Rev est $179.27M
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $17.47

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields.

Sector

Healthcare

Industry

Medical Instruments/Supply